Dyslipidemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Dyslipidemia (US)
Dyslipidemia, characterized by abnormal lipid levels, plays a pivotal role in the development of cardiovascular (CV) disease. Physicians address this risk with various lipid-modifying therapies such as statins, ezetimibe, fibrates, omega-3 fatty acids, and PCSK9 inhibitors. Statins are particularly notable for their favorable risk-benefit profile and strong evidence of their ability to reduce CV morbidity and mortality. Nevertheless, the treatment landscape extends beyond statins; numerous later-line therapies offer additional options for lipid management and reduction in CV risk. Using longitudinal claims data analysis, we explore the treatment of newly diagnosed and recently treated dyslipidemia patients in the United States.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed dyslipidemia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed dyslipidemia patients?
- How have PCSK9 inhibitors (Praluent, Repatha, and Leqvio) been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of dyslipidemia patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
- What percentage of dyslipidemia patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States
Key companies: Amarin, Esperion Therapeutics, Amgen, Novartis, Regeneron, Merck & Co., Pfizer, AstraZeneca, Kowa Pharmaceuticals, Medicure Pharmaceuticals
Key drugs: Statins, fibrates, Leqvio, Nexlizet, and Repatha
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Key feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses
